Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

Researchers are probing its efficacy in patients with Type 2 inflammatory diseases, which are triggered by an overactive ...

Moderate-to-severe atopic dermatitis is associated with higher lifetime prevalence of multimorbidity and increased odds of ...

Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.

Still itching after topical steroids? Here's why your atopic dermatitis symptoms may still be flaring and what you can do about it.

In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...